Boehringer acquires T3 Pharma, a clinical stage Swiss biotech company.
Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF. T3 Pharma has developed a proprietary therapy platform that uses live bacteria to…